Induction of antigen-specific immune tolerance using biodegradable nanoparticles containing antigen and dexamethasone

References

• Mellman I. Dendritic cells: master regulators of the immune response. Cancer Immunol Res. 2013;1(3):145–149. doi:10.1158/2326-6066.CIR-13-010224777676
   PubMed Web of Science ®Google Scholar
• Gerner MY, Casey KA, Kastenmuller W, Germain RN. Dendritic cell and antigen dispersal landscapes regulate T cell immunity. J Exp Med. 2017;214(10):3105–3122. doi:10.1084/jem.2017033528847868
   PubMedGoogle Scholar
• Kim JU, Kim M, Kim S, et al. Dendritic cell dysfunction in patients with end-stage renal disease. Immune Netw. 2017;17(3):152–162. doi:10.4110/in.2017.17.3.15228680376
   PubMed Web of Science ®Google Scholar
• Audiger C, Rahman MJ, Yun TJ, Tarbell KV, Lesage S. The importance of dendritic cells in maintaining immune tolerance. J Immunol. 2017;198(6):2223–2231. doi:10.4049/jimmunol.160162928264998
   PubMedGoogle Scholar
• Hubo M, Trinschek B, Kryczanowsky F, Tuettenberg A, Steinbrink K, Jonuleit H. Costimulatory molecules on immunogenic versus tolerogenic human dendritic cells. Front Immunol. 2013;4:82. doi:10.3389/fimmu.2013.0008223565116
   PubMed Web of Science ®Google Scholar
• Vander Lugt B, Riddell J, Khan AA, et al. Transcriptional determinants of tolerogenic and immunogenic states during dendritic cell maturation. J Cell Biol. 2017;216(3):779–792. doi:10.1083/jcb.20151201228130292
   PubMedGoogle Scholar
• Hwang WB, Kim DJ, Oh GS, Park JH. Aryl hydrocarbon receptor ligands indoxyl 3-sulfate and indole-3-carbinol inhibit FMS-like tyrosine kinase 3 ligand-induced bone marrow-derived plasmacytoid dendritic cell differentiation. Immune Netw. 2018;18(5):e35. doi:10.4110/in.2018.18.e3530402330
   PubMedGoogle Scholar
• Kalantari T, Kamali-Sarvestani E, Ciric B, et al. Generation of immunogenic and tolerogenic clinical-grade dendritic cells. Immunol Res. 2011;51(2–3):153–160. doi:10.1007/s12026-011-8255-522105838
   PubMedGoogle Scholar
• Kim SH, Jung HH, Lee CK. Generation, Characteristics and clinical trials of ex vivo generated tolerogenic dendritic cells. Yonsei Med J. 2018;59(7):807–815. doi:10.3349/ymj.2018.59.7.80730091313
   PubMedGoogle Scholar
• Domogalla MP, Rostan PV, Raker VK, Steinbrink K. Tolerance through education: how tolerogenic dendritic cells shape immunity. Front Immunol. 2017;8:1764. doi:10.3389/fimmu.2017.0176429375543
   PubMedGoogle Scholar
• Unger WW, Laban S, Kleijwegt FS, van der Slik AR, Roep BO. Induction of Treg by monocyte-derived DC modulated by vitamin D3 or dexamethasone: differential role for PD-L1. Eur J Immunol. 2009;39(11):3147–3159. doi:10.1002/eji.20083910319688742
   PubMed Web of Science ®Google Scholar
• Tuettenberg A, Huter E, Hubo M, et al. The role of ICOS in directing T cell responses: ICOS-dependent induction of T cell anergy by tolerogenic dendritic cells. J Immunol. 2009;182(6):3349–3356. doi:10.4049/jimmunol.080273319265111
   PubMed Web of Science ®Google Scholar
• Ahmed MS, Bae YS. Dendritic cell-based immunotherapy for rheumatoid arthritis: from bench to bedside. Immune Netw. 2016;16(1):44–51. doi:10.4110/in.2016.16.1.4426937231
   PubMedGoogle Scholar
• Tai N, Yasuda H, Xiang Y, et al. IL-10-conditioned dendritic cells prevent autoimmune diabetes in NOD and humanized HLA-DQ8/RIP-B7.1 mice. Clin Immunol. 2011;139(3):336–349. doi:10.1016/j.clim.2011.03.00321458378
   PubMed Web of Science ®Google Scholar
• Chorny A, Gonzalez-Rey E, Fernandez-Martin A, Pozo D, Ganea D, Delgado M. Vasoactive intestinal peptide induces regulatory dendritic cells with therapeutic effects on autoimmune disorders. Proc Natl Acad Sci U S A. 2005;102(38):13562–13567. doi:10.1073/pnas.050448410216150720
   PubMed Web of Science ®Google Scholar
• Horibe EK, Sacks J, Unadkat J, et al. Rapamycin-conditioned, alloantigen-pulsed dendritic cells promote indefinite survival of vascularized skin allografts in association with T regulatory cell expansion. Transpl Immunol. 2008;18(4):307–318. doi:10.1016/j.trim.2007.10.00718158116
   PubMedGoogle Scholar
• Benham H, Nel HJ, Law SC, et al. Citrullinated peptide dendritic cell immunotherapy in HLA risk genotype-positive rheumatoid arthritis patients. Sci Transl Med. 2015;7(290):290ra287. doi:10.1126/scitranslmed.aad3106
   Web of Science ®Google Scholar
• Giannoukakis N, Phillips B, Finegold D, Harnaha J, Trucco M. Phase I (safety) study of autologous tolerogenic dendritic cells in type 1 diabetic patients. Diabetes Care. 2011;34(9):2026–2032. doi:10.2337/dc11-047221680720
   PubMed Web of Science ®Google Scholar
• Nafarrate IZ, Florez G, Vila G, et al. Phase 1b clinical trial with antigen-specific tolerogenic dendritic in multiple sclerosis and neuromyelitis optica: safety and immunological effects (P2.330). Neurology. 2017;88(Suppl 16):P2.330. doi:10.1212/WNL.0000000000003693
   Google Scholar
• Jauregui-Amezaga A, Cabezon R, Ramirez-Morros A, et al. Intraperitoneal administration of autologous tolerogenic dendritic cells for refractory Crohn’s disease: a phase I study. J Crohns Colitis. 2015;9(12):1071–1078. doi:10.1093/ecco-jcc/jjv14426303633
   PubMedGoogle Scholar
• Paragliola RM, Papi G, Pontecorvi A, Corsello SM. Treatment with synthetic glucocorticoids and the hypothalamus-pituitary-adrenal axis. Int J Mol Sci. 2017;18(10):2201. doi:10.3390/ijms18102201
   PubMed Web of Science ®Google Scholar
• Gustafson MP, Lin Y, New KC, et al. Systemic immune suppression in glioblastoma: the interplay between CD14+HLA-DRlo/neg monocytes, tumor factors, and dexamethasone. Neuro Oncol. 2010;12(7):631–644. doi:10.1093/neuonc/noq00120179016
   PubMed Web of Science ®Google Scholar
• Baschant U, Tuckermann J. The role of the glucocorticoid receptor in inflammation and immunity. J Steroid Biochem Mol Biol. 2010;120(2–3):69–75. doi:10.1016/j.jsbmb.2010.03.05820346397
   PubMed Web of Science ®Google Scholar
• Rozkova D, Horvath R, Bartunkova J, Spisek R. Glucocorticoids severely impair differentiation and antigen presenting function of dendritic cells despite upregulation of Toll-like receptors. Clin Immunol. 2006;120(3):260–271. doi:10.1016/j.clim.2006.04.56716765091
   PubMedGoogle Scholar
• Piemonti L, Monti P, Allavena P, et al. Glucocorticoids affect human dendritic cell differentiation and maturation. J Immunol. 1999;162(11):6473–6481.10352262
   PubMed Web of Science ®Google Scholar
• Matyszak MK, Citterio S, Rescigno M, Ricciardi-Castagnoli P. Differential effects of corticosteroids during different stages of dendritic cell maturation. Eur J Immunol. 2000;30(4):1233–1242. doi:10.1002/(SICI)1521-4141(200004)30:4<1233::AID-IMMU1233>3.0.CO;2-F10760813
   PubMedGoogle Scholar
• Lee JH, Park CS, Jang S, et al. Tolerogenic dendritic cells are efficiently generated using minocycline and dexamethasone. Sci Rep. 2017;7(1):15087. doi:10.1038/s41598-017-15569-129118423
   PubMedGoogle Scholar
• Boumpas DT, Paliogianni F, Anastassiou ED, Balow JE. Glucocorticosteroid action on the immune system: molecular and cellular aspects. Clin Exp Rheumatol. 1991;9(4):413–423.1934694
   PubMed Web of Science ®Google Scholar
• Marx J. How the glucocorticoids suppress immunity. Science. 1995;270(5234):232–233.7569969
   PubMed Web of Science ®Google Scholar
• Coutinho AE, Chapman KE. The anti-inflammatory and immunosuppressive effects of glucocorticoids, recent developments and mechanistic insights. Mol Cell Endocrinol. 2011;335(1):2–13. doi:10.1016/j.mce.2010.04.00520398732
   PubMed Web of Science ®Google Scholar
• Liu D, Ahmet A, Ward L, et al. A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy. Allergy Asthma Clin Immunol. 2013;9(1):30. doi:10.1186/1710-1492-9-3023947590
   PubMed Web of Science ®Google Scholar
• Vardy J, Chiew KS, Galica J, Pond GR, Tannock IF. Side effects associated with the use of dexamethasone for prophylaxis of delayed emesis after moderately emetogenic chemotherapy. Br J Cancer. 2006;94(7):1011–1015. doi:10.1038/sj.bjc.660304816552437
   PubMedGoogle Scholar
• Moni SS, Safhi MM, Barik BB. Nanoparticles for triggering and regulation of immune response of vaccines: perspective and prospective. Curr Pharm Biotechnol. 2013;14(15):1242–1249.25106651
   PubMed Web of Science ®Google Scholar
• Hamdy S, Haddadi A, Hung RW, Lavasanifar A. Targeting dendritic cells with nano-particulate PLGA cancer vaccine formulations. Adv Drug Deliv Rev. 2011;63(10–11):943–955. doi:10.1016/j.addr.2011.05.02121679733
   PubMed Web of Science ®Google Scholar
• Elamanchili P, Diwan M, Cao M, Samuel J. Characterization of poly(D,L-lactic-co-glycolic acid) based nanoparticulate system for enhanced delivery of antigens to dendritic cells. Vaccine. 2004;22(19):2406–2412. doi:10.1016/j.vaccine.2003.12.03215193402
   PubMed Web of Science ®Google Scholar
• Lee YH, Lee YR, Kim KH, et al. Baccatin III, a synthetic precursor of taxol, enhances MHC-restricted antigen presentation in dendritic cells. Int Immunopharmacol. 2011;11(8):985–991. doi:10.1016/j.intimp.2011.02.01321354357
   PubMedGoogle Scholar
• Lee Y, Im SA, Kim J, et al. Modified aloe polysaccharide restores chronic stress-induced immunosuppression in mice. Int J Mol Sci. 2016;17(10). doi:10.3390/ijms17101660
   Web of Science ®Google Scholar
• Lee YR, Lee YH, Im SA, et al. Biodegradable nanoparticles containing TLR3 or TLR9 agonists together with antigen enhance MHC-restricted presentation of the antigen. Arch Pharm Res. 2010;33(11):1859–1866. doi:10.1007/s12272-010-1119-z21116790
   PubMedGoogle Scholar
• Lee YR, Lee YH, Im SA, Kim K, Lee CK. Formulation and characterization of antigen-loaded PLGA nanoparticles for efficient cross-priming of the antigen. Immune Netw. 2011;11(3):163–168. doi:10.4110/in.2011.11.3.16321860609
   PubMedGoogle Scholar
• Jiang W, Gupta RK, Deshpande MC, Schwendeman SP. Biodegradable poly(lactic-co-glycolic acid) microparticles for injectable delivery of vaccine antigens. Adv Drug Deliv Rev. 2005;57(3):391–410. doi:10.1016/j.addr.2004.09.00315560948
   PubMed Web of Science ®Google Scholar
• Waeckerle-Men Y, Groettrup M. PLGA microspheres for improved antigen delivery to dendritic cells as cellular vaccines. Adv Drug Deliv Rev. 2005;57(3):475–482. doi:10.1016/j.addr.2004.09.00715560953
   PubMed Web of Science ®Google Scholar
• Shen H, Ackerman AL, Cody V, et al. Enhanced and prolonged cross-presentation following endosomal escape of exogenous antigens encapsulated in biodegradable nanoparticles. Immunology. 2006;117(1):78–88. doi:10.1111/j.1365-2567.2005.02268.x16423043
   PubMed Web of Science ®Google Scholar
• Allahyari M, Mohit E. Peptide/protein vaccine delivery system based on PLGA particles. Hum Vaccin Immunother. 2016;12(3):806–828. doi:10.1080/21645515.2015.110280426513024
   PubMed Web of Science ®Google Scholar
• Gerelchuluun T, Lee YH, Lee YR, et al. Dendritic cells process antigens encapsulated in a biodegradable polymer, poly(D,L-lactide-co-glycolide), via an alternate class I MHC processing pathway. Arch Pharm Res. 2007;30(11):1440–1446.18087813
   PubMed Web of Science ®Google Scholar
• Xia CQ, Peng R, Beato F, Clare-Salzler MJ. Dexamethasone induces IL-10-producing monocyte-derived dendritic cells with durable immaturity. Scand J Immunol. 2005;62(1):45–54. doi:10.1111/j.1365-3083.2005.01640.x16091124
   PubMedGoogle Scholar
• Xiang SD, Scholzen A, Minigo G, et al. Pathogen recognition and development of particulate vaccines: does size matter? Methods. 2006;40(1):1–9. doi:10.1016/j.ymeth.2006.05.01616997708
   PubMed Web of Science ®Google Scholar
• Mottram PL, Leong D, Crimeen-Irwin B, et al. Type 1 and 2 immunity following vaccination is influenced by nanoparticle size: formulation of a model vaccine for respiratory syncytial virus. Mol Pharm. 2007;4(1):73–84. doi:10.1021/mp060096p17274665
   PubMedGoogle Scholar
• Zhao F, Zhao Y, Liu Y, Chang X, Chen C, Zhao Y. Cellular uptake, intracellular trafficking, and cytotoxicity of nanomaterials. Small. 2011;7(10):1322–1337. doi:10.1002/smll.20110000121520409
   PubMed Web of Science ®Google Scholar
• Sadat SMA, Jahan ST, Haddadi A. Effects of size and surface charge of polymeric nanoparticles on in vitro and in vivo applications. J Biomater Nanobiotechnol. 2016;7(2):91–108. doi:10.4236/jbnb.2016.72011
   Google Scholar
• Jia J, Zhang Y, Xin Y, Jiang C, Yan B, Zhai S. Interactions between nanoparticles and dendritic cells: from the perspective of cancer immunotherapy. Front Oncol. 2018;8:404. doi:10.3389/fonc.2018.0040430319969
   PubMed Web of Science ®Google Scholar